Stiksma et al. found that patients with elevated preoperative CA19-9 levels had worse 5-year survival than patients with elevated preoperative CEA levels, and suggested that CA19-9 be used to monitor disease progression in CRC patients without elevated CEA [17]. Here, CEACAM5 is linked to colorectal carcinoma.